New Techniques for Management of 'Inoperable' Gliomas radically challenges the assumption that certain gliomas cannot be removed with modern techniques, contesting stereotypical thinking and establishing new paradigms in the field. Gliomas are primary brain tumors which are often fatal. Recent data has demonstrated that despite the fact that surgery cannot cure gliomas, patient survival is substantially improved by removing as much of the tumor as possible. This fact has raised the imperative that neurologists try to improve techniques to bring surgical resection to as many patients as possible. This book brings new insights and technologies to the forefront, giving hope to patients.

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant.? Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts to highlight the latest updates on various forms of management of high grade glioma.? Some of the articles included in this issue focus on Extent of Resection for Glioblastoma; Role of adjuvant radiation therapy; Survival benefit of the Temozolomide protocol; Alternative chemotherapeutic agents; The role of avastin; Radiology; Pseuodprogression and Treatment effect; Pathology; Medical Management; Management of insular gliomas; Use of motor mapping; GBM treatment with clinical trials for surgical resection; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Future role of CED for GBM treatment; Application of a vault nanoparticle therapy for GBM therapy; Management of high grade gliomas in pediatric populations; Targeting Glioma Stem Like Cells with a focus on CD 133; and Potential Role for STAT3 inhibitors in glioblastoma.

For this issue, Dr. Michael Lim of Johns Hopkins and Dr. Isaac Yang of UCSF team up to deliver a packed issue on the latest developments in Immunotherapy.? The issue covers hot topics such as immunostimulants, Passive Antibody Mediated Immunotherapy, Clinical Applications of A Peptide Based Vaccine, Challenges for Clinical Design of Immunotherapy Trials, The EGFRv3 Peptide Vaccine, Stem Cell Therapy and Dendritic Cell Vaccines, Dendritic Glioma Fusion Vaccine, Adoptive Cellular Immunotherapy, Virus Mediated Immunotherapy, and so much more.